Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction
Tord Inghardt, Thomas Antonsson, Cecilia Ericsson, Daniel Hovdal, Petra Johannesson, Carina Johansson, Ulrik Jurva, Johan Kajanus, Bengt Kull, Erik Michaëlsson, Anna Pettersen, Tove Sjögren, Henrik Toft Sørensen, Kristina Westerlund, Eva‐Lotte Lindstedt
Abstract
/3 efficacy study of AZD4831 in patients with HFpEF started in 2021.
Topics & Concepts
ChemistryMyeloperoxidasePharmacologyPotencyHeart failurePharmacokineticsIn vitroEjection fractionInternal medicineBiochemistryMedicineInflammationNeutrophil, Myeloperoxidase and Oxidative MechanismsNitric Oxide and Endothelin EffectsCardiac Ischemia and Reperfusion